NeOnc Technologies Holdings, Inc. filed a formal corporate presentation for use in upcoming investor meetings, highlighting its clinical-stage CNS oncology platforms. The filing includes a clinical update for the NEO100 Phase 2a study, reporting an additional patient response that increased the objective response rate from 8.3% to 12.5%.
Neonc Technologies Holdings CEO, President Amir F. Heshmatpour Buys $151K of Stock
Amir F. Heshmatpour, CEO, President, bought 30,000 shares of Neonc Technologies Holdings, Inc. at $5.02 a share, worth $151K in total on Nov 13, 2026. Shares held after the trade: 3,353,000 (+0.9%).
NeOnc Technologies announced that CEO Amir Heshmatpour purchased 80,000 shares of common stock in the open market, bringing his total 2026 personal investment to 271,000 shares. Additionally, the company received a Type B End-of-Phase meeting from the FDA scheduled for January 2027 to discuss an accelerated approval pathway for its brain cancer candidate, NEO100.
Neonc Technologies Holdings CMO Thomas C. Chen Buys $10K of Stock
Thomas C. Chen, CMO, bought 2,284 shares of Neonc Technologies Holdings, Inc. at $4.38 a share, worth $10K in total on Nov 10, 2026. Shares held after the trade: 29,519 (+8.4%).
Neonc Technologies Holdings CEO, President Amir F. Heshmatpour Buys $294K of Stock
Amir F. Heshmatpour, CEO, President, bought 70,000 shares of Neonc Technologies Holdings, Inc. at $4.00 to $4.49 a share (average $4.21) in 3 transactions, worth $294K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 3,333,000 (+0.3%).
Neonc Technologies Holdings CEO, President Amir F. Heshmatpour Buys $38.6K of Stock
Amir F. Heshmatpour, CEO, President, bought 10,000 shares of Neonc Technologies Holdings, Inc. at $3.86 a share, worth $38.6K in total on Nov 9, 2026. Shares held after the trade: 3,263,000 (+0.3%).
Neonc Technologies Holdings CEO, President Amir F. Heshmatpour Buys $231K of Stock
Amir F. Heshmatpour, CEO, President, bought 70,000 shares of Neonc Technologies Holdings, Inc. at $3.17 to $3.39 a share (average $3.29) in 2 transactions, worth $231K in total between Nov 5, 2026 and Nov 6, 2026. Shares held after the trade: 3,253,000 (+1.2%).
NeOnc Technologies reported Q3 2026 financial results, highlighting a narrowed net loss of $4.4 million compared to $8.6 million in the prior year period. The company also noted clinical progress with positive topline Phase 2a results for its NEO100 program and a $15 million capital raise completed in September.
Term
Q3 2026
“The third quarter marked a period of meaningful progress for NeOnc, strengthening our clinical programs, our balance sheet and our international presence. In August, we were pleased to report positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint, an important milestone that supports the potential of our intranasal approach to directly address delivery across the blood-brain barrier, one of the greatest challenges in treating brain cancer.”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer
“Alongside these clinical achievements, we strengthened the financial and strategic foundation that supports them. In September, we raised $15 million from new and existing healthcare-focused institutional investors and used a portion of the proceeds to redeem all of our Series A Convertible Preferred Stock in cash, eliminating its potential dilution for our shareholders.”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer
For the nine months ended September 30, 2026, NeoNc Technologies reported a net loss of $27.5 million, an improvement from the $46.6 million loss in the prior year period. The company significantly strengthened its cash position to $6.2 million through various private placements and equity offerings, though it continues to operate with a stockholders' deficit of $13.2 million.
NeOnc Technologies announced it will present data from its NEO100 and NEO212 clinical programs at the 31st Annual Meeting of the Society for Neuro-Oncology in November 2026. The presentations will cover Phase 1/2a results for intranasal NEO100 in astrocytoma and Phase 1 safety and PK data for oral NEO212 in recurrent GBM. This filing serves as an announcement of the upcoming presentations and does not disclose the specific clinical results or data points.
NeOnc Technologies reported early clinical improvement in the first pediatric patient treated with its investigational intranasal NEO100 under a Compassionate Care program in Abu Dhabi. The company also announced a Memorandum of Understanding with the Department of Health – Abu Dhabi to cooperate on oncology and CNS therapeutic research.
NeOnc Technologies appointed Ali Mohammad Ahmad Alabedin, Group Head of Islamic Banking at First Abu Dhabi Bank, to its Board of Directors as a Class I director. He succeeds Dr. Steven L. Giannotta, who resigned from the Board but will continue to serve on the company's Scientific Advisory Board. The appointment is intended to strengthen financial governance as the company expands its clinical development activities in Abu Dhabi.
NeOnc Technologies has scheduled an in-person End-of-Phase 1 Type B meeting with the FDA for November 17, 2026, to discuss the clinical development of NEO212. The company intends to seek feedback on Phase 2 study design, patient populations, and potential accelerated approval pathways following encouraging Phase 1 results in glioblastoma and brain metastases.
NeOnc Technologies redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for approximately $5.79 million in cash. The redemption was funded by proceeds from a recent $15 million registered direct offering to eliminate potential dilution from the preferred stock's conversion features and simplify the company's capital structure.
Neonc Technologies Holdings CFO Keithly Garnett Sells $16.8K of Stock
Keithly Garnett, CFO, sold 5,000 shares of Neonc Technologies Holdings, Inc. at $3.36 a share, worth $16.8K in total on Sep 15, 2026. Shares held after the trade: 237,357 (+2.2%).